Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with Shanghai Jiao Tong University (SJTU) for MCB-166, a novel antidepressant drug candidate. The partnership marks Shanghai Pharma’s strategic expansion into innovative mental health therapeutics through academic collaboration, leveraging SJTU’s research capabilities to diversify beyond its traditional distribution and generics-focused portfolio.
Transaction Overview
Element
Detail
Licensor
Shanghai Jiao Tong University (SJTU)
Licensee
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607)
Asset
MCB-166 (antidepressant drug candidate)
Mechanism
Novel mechanism of action (specific target undisclosed)
Deal Type
Academic-industry licensing agreement
Signing Date
24 Mar 2026
Strategic Rationale & Pipeline Expansion
Shanghai Pharma Position
SJTU Contribution
Combined Value
Distribution dominance – 30,000+ hospital network, government procurement expertise
Development Timeline: Likely IND-enabling studies 2026–2027; Phase I initiation 2028 assuming preclinical milestones met
Commercial Potential: Novel antidepressants command premium pricing (vs. generic SSRIs); peak sales RMB 500+ million if approved with differentiated efficacy/safety
Forward‑Looking Statements This brief contains forward‑looking statements regarding preclinical development progress, IND filing timelines, and commercial potential for MCB-166. Actual results may differ due to mechanism validation challenges, competitive dynamics in the crowded antidepressant space, and regulatory requirements for novel CNS drug approval.-Fineline Info & Tech
By Fineline Cube 